Palvella Therapeutics
Develops topical QTORIN candidates for serious rare skin diseases and vascular malformations.
Something off on this page? Send us feedback.
Profile
Develops topical QTORIN product candidates for rare skin diseases and vascular malformations with no approved products yet. The pipeline centers on QTORIN rapamycin, with QTORIN pitavastatin earlier in development, and the business relies on clinical progress, regulatory approval, third-party execution, and formulation intellectual property.
Develops topical QTORIN formulations for serious rare skin diseases and vascular malformations, with no approved commercial products or product revenue yet. The lead program is QTORIN rapamycin for microcystic lymphatic malformations, with additional rapamycin programs for cutaneous venous malformations and clinically significant angiokeratomas.
The pipeline also includes QTORIN pitavastatin for disseminated superficial actinic porokeratosis. Operations are concentrated in the United States through a small Wayne, Pennsylvania-based clinical-stage organization, and the company reports one operating segment.
Execution depends on clinical development, regulatory review, third-party manufacturers and research partners, and protection of formulation intellectual property around active ingredients that are not themselves patent-protected. Future revenue depends on approval and commercialization of product candidates.
Company facts
Key statistics
Year to date +49.6% · Average volume (30d) 197.8K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Truist Financial | Target | $210 | $207 | |
| Aug 5, 2026 | Canaccord Genuity | Target | $204 | $232 | |
| Jul 22, 2026 | H.C. Wainwright | Reiterate | Buy | $255 | $270 |
| May 12, 2026 | Stephens | Target | $220 | ||
| Feb 24, 2026 | Truist Financial | Target | $190 | $210 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$1.17 | −$1.52 | −29.9% | — | — | — | +7.96% |
| May 7, 2026Q1 FY26 | −$0.90 | −$1.20 | −33.3% | — | — | — | +7.09% |
| Mar 31, 2026Q4 FY25 | −$0.91 | −$1.08 | −18.5% | — | — | — | −3.43% |
| Nov 11, 2025Q3 FY25 | −$0.85 | −$1.03 | −21.2% | — | — | — | +4.74% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$7.9M | −$9.3M | −$10.2M | −$11.3M | −$14.9M | −$21.4M | |
| Net income | −$8.2M | −$9.5M | −$11.3M | −$12.7M | −$15.8M | −$21.9M | |
| Diluted EPS | −$3.68 | −$0.86 | −$1.03 | −$1.08 | −$1.20 | −$1.52 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $42.8M · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $250.6M · Total debt $535.0K · Total assets $253.5M · Shareholders' equity $216.9M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 14.34M · Float 9.62M · 67.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 1.14M | 7.92% | 13F | Aug 14, 2026 |
| Prudential Financial Inc | 962.4K | 6.70% | 13G | Aug 10, 2026 |
| Jennison Associates LLC | 960.6K | 6.70% | 13G | Aug 3, 2026 |
| Frazier Life Sciences Management, L.P. | 882.4K | 6.15% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 813.0K | 5.70% | 13G | Jul 29, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $152.21 |
| Jul 15, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $149.28 |
| Jun 17, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $110.73 |
| May 20, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $110.56 |
| Apr 15, 2026 | Kathleen Goin | officer: Chief Operating Officer | −4,302 | $127.24 |
Peers
- Novartis (ADR)
Approved PROS vascular-anomaly therapy with Vijoice
- Protara Therapeutics
Phase 2 lymphatic-malformation program with TARA-002
- Relay Therapeutics
PI3Kalpha vascular-anomaly program with zovegalisib
- Krystal Biotech
Topical rare-skin gene therapy commercialized as VYJUVEK
- Pfizer
Established oral sirolimus franchise with Rapamune
- Abeona Therapeutics
Autologous rare-skin gene therapy commercialized as ZEVASKYN
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Palvella Therapeutics | $149.97 | 0.00% | $2.15B | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Protara Therapeutics | $3.82 | +0.26% | $214.7M | — | — | — | — |
| Relay Therapeutics | $19.10 | +1.82% | $4.11B | — | — | 397.4 | −48.3% |
| Krystal Biotech | $351.46 | +0.05% | $10.36B | 44.0 | 41.3 | 23.5 | +24.1% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Abeona Therapeutics | $5.97 | +0.67% | $337.4M | — | — | 13.2 | +2,745.0% |
| Median | 36.9 | 16.4 | 13.2 | +2.6% |